Related Experiment Videos
Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma
A J O'Neill1, S A Boran, C O'Keane
1Department of Surgery, Mater Misericordiae Hospital, University College Dublin, Conway Institute of Biomolecular and Biomedical Research, Dublin, Ireland.
The Prostate
|May 15, 2001
Summary
Altered caspase 3 expression is observed in prostate cancer, potentially contributing to resistance against androgen ablation therapy. This finding highlights a new mechanism for apoptotic resistance in prostate cancer treatment.
Area of Science:
- Oncology
- Cell Biology
- Urology
Background:
- Prostate cancer treatment faces challenges due to resistance to androgen ablation.
- Overexpression of antiapoptotic proteins (e.g., Bcl-2) and p53 mutations contribute to this resistance.
- Caspase proteases, executioners of cell death, are present in prostate cells, and their altered expression may influence resistance.
Purpose of the Study:
- To investigate the expression of caspase 3 in benign prostatic hyperplasia (BPH) and prostate cancer tissues.
- To determine if altered caspase 3 expression correlates with resistance to androgen ablation in prostate cancer.
Main Methods:
- Immunohistochemistry was used to assess caspase 3 expression.
- Formalin-fixed, paraffin-embedded tissue sections from 22 patients with prostate cancer and BPH were analyzed.
- Specimens were obtained from patients undergoing prostate surgical resection.
Main Results:
- Caspase 3 was expressed in 81.1% (18/22) of samples.
- High caspase 3 expression was noted in BPH, with staining in both basal and secretory epithelial cells.
- Prostate cancers showed a significant loss of caspase 3 expression in secretory epithelial cells, particularly in high-grade carcinomas.
Conclusions:
- Altered caspase 3 expression may be an additional mechanism contributing to apoptotic resistance in prostate cancer.
- This finding suggests a potential role for caspase 3 modulation in overcoming treatment resistance.
- Further research into caspase 3's role could lead to improved therapeutic strategies for prostate cancer.